Nav: Home

NSAIDs modulate biomarker panel for esophageal adenocarcinoma

February 26, 2007

Nonsteroidal anti-inflammatory drugs may give some protection against esophageal adenocarcinoma developing from its premalignant state, Barrett's esophagus.

Genetic abnormalities are common in many human cancers and their precursors, including esophageal adenocarcinoma and Barrett's esophagus. Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed as possible chemoprevention against esophageal adenocarcinoma and Barrett's esophagus.

A study of 243 patients with Barrett's esophagus followed up for 10 years by Patricia Galipeau and colleagues from the Fred Hutchinson Cancer Research Center, Seattle looked at various genetic changes, including specific mutations and variations in the total amount of DNA present. They assessed whether each genetic abnormality was associated with the risk of developing esophageal adenocarcinoma, and whether the risk was altered in patients who had taken aspirin or other NSAIDs.

The researchers found that over 10 y, all abnormalities, except two, contributed significantly to the risk of developing esophageal adenocarcinoma. A panel of genetic abnormalities was the best predictor of developing esophageal adenocarcinoma; over 10 years patients with no baseline abnormality had a 12% cumulative incidence of esophageal adenocarcinoma, whereas patients with the full panel of genetic abnormalities had a 79% incidence. In patients with none, one, two, or three baseline genetic abnormalities, the risk of developing esophageal adenocarcinoma was significantly reduced among users of NSAIDs compared to nonusers, with the strongest protective effect being seen in participants with multiple genetic abnormalities.

These findings may have implications for the treatment of patient with Barrett's esophagus, but especially since this is an observational study, and not a randomised trial, it will need to be confirmed in other groups of patients.
EMBARGO: MONDAY, 26 February, 5 P.M. PDT

Everything published by PLoS Medicine is Open Access: freely available for anyone to read, download, redistribute and otherwise use, as long as the authorship is properly attributed.

Please mention PLoS Medicine in your report and use the links below to take your readers straight to the online articles:

Citation: Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, et al. (2007) NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4(2): e67.



Patricia Galipeau
Fred Hutchinson Cancer Research Center
Human Biology
1100 Fairview Ave N C1-157
PO BOX 19024
Seattle, WA 98109 United States of America
+1 206-667-4615
+1 206-667-6132 (fax)


Related Aspirin Articles:

Benefit seen for ticagrelor alone, without aspirin, in patients with ACS
The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Study: An aspirin a day does not keep dementia at bay
Taking a low-dose aspirin once a day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or probable Alzheimer's disease, nor does it slow the rate of cognitive decline, according to a large study published in the March 25, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Aspirin's health benefits under scrutiny
Taking a baby aspirin every day to prevent a heart attack or stroke should no longer be recommended to patients who haven't already experienced one of these events.
Aspirin may no longer be effective as cardiovascular treatment
A new paper in Family Practice, published by Oxford University Press, found that the widespread use of statins and cancer screening technology may have altered the benefits of aspirin use.
Migraine headaches? Consider aspirin for treatment and prevention
Evidence from 13 randomized trials of the treatment of migraine in 4,222 patients and tens of thousands of patients in prevention of recurrent attacks supports the use of high dose aspirin from 900 to 1,300 milligrams to treat acute migraine as well as low dose daily aspirin from 81 to 325 milligrams to prevent recurrent attacks.
Aspirin use after biliary tract cancer diagnosis
Researchers in this observational study examined if aspirin use after a diagnosis of a biliary tract cancer, which includes gallbladder cancer, was associated with reduced risk of death among nearly 3,000 patients.
Aspirin may prevent air pollution harms
A new study is the first to report evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin may lessen the adverse effects of air pollution exposure on lung function.
Aspirin should not be recommended for healthy people over 70
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease.
Frequent use of aspirin can lead to increased bleeding
A new study published today in the Journal of the American Medical Association (JAMA) has found that taking aspirin on a regular basis to prevent heart attacks and strokes, can lead to an increase risk of almost 50 percent in major bleeding episodes.
Analyzing aspirin use in patients without cardiovascular disease
This study analyzed combined results from 13 randomized clinical trials with more than 164,000 participants to assess aspirin use with the prevention of cardiovascular events and bleeding in people without cardiovascular disease.
More Aspirin News and Aspirin Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at